The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice

Journal of Clinical Investigation

Volumn 120, Issue 7, 2010, Pages 2457-2473

  Greenblatt, Matthew B ^a,b   Shim, Jae Hyuck ^a,b   Zou, Weiguo ^a,b   Sitara, Despina ^a,b   Schweitzer, Michelle ^a,b   Hu, Dorothy ^a,b   Lotinun, Sutada ^c   Sano, Yasuyo ^d   Baron, Roland ^c   Park, Jin Mo ^d   Arthur, Simon ^e   Xie, Min ^f   Schneider, Michael D ^g   Zhai, Bo ^b   Gygi, Steven ^b   Davis, Roger ^h   Glimcher, Laurie H ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; CREBBP PROTEIN, HUMAN; MAP KINASE KINASE KINASE 7; MAP3K8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

AGING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DEVELOPMENT; BONE MALFORMATION; BONE METABOLISM; CLEIDOCRANIAL DYSPLASIA; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELL DIFFERENTIATION; CREB-BINDING PROTEIN; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 14; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOBLASTS; OSTEOGENESIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77954972964     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42285     Document Type: Article

References (57)

1. Gerstenfeld LC, Chipman SD, Glowacki J, Lian JB. Expression of differentiated function by mineralizing cultures of chicken osteoblasts. Dev Biol. 1987;122(1):49-60.
2. Li H, et al. Expression and function of Dlx genes in the osteoblast lineage. Dev Biol. 2008;316(2):458-470.
3. Bialek P, et al. A twist code determines the onset of osteoblast differentiation. Dev Cell. 2004; 6(3):423-435.
4. Karsenty G, et al. Cbfa1 as a regulator of osteoblast differentiation and function. Bone. 1999; 25(1):107-108.
5. Nakashima K, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108(1):17-29.
6. Koga T, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005;11(8):880-885.
7. Glass DA 2nd, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751-764.
8. Yang X, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 2004; 117(3):387-398.
9. Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 2008;9:183-196.
10. Otto F, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89(5):765-771.
11. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89(5):747-754.
12. Mundlos S, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 1997;89(5):773-779.
13. Lee B, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet. 1997;16(3):307-310.
14. Lou Y, et al. A Runx2 threshold for the cleidocranial dysplasia phenotype. Hum Mol Genet. 2009;18(3):556-568.
15. Suzuki A, et al. Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone. 2002; 30(1):91-98.
16. Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T. JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res. 2009;24(3):398-410.
17. Xiao G, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem. 2000;275(6):4453-4459.
18. Ge C, Xiao G, Jiang D, Franceschi RT. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol. 2007;176(5):709-718.
19. Matsushita T, Chan YY, Kawanami A, Balmes G, Landreth GE, Murakami S. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol. 2009;29(21):5843-5857.
20. Rey A, Manen D, Rizzoli R, Ferrari SL, Caverzasio J. Evidences for a role of p38 MAP kinase in the stimulation of alkaline phosphatase and matrix mineralization induced by parathyroid hormone in osteoblastic cells. Bone. 2007;41(1):59-67. (Pubitemid 46891895)
21. Zhou FH, Foster BK, Zhou XF, Cowin AJ, Xian CJ. TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J Bone Miner Res. 2006;21(7):1075-1088.
22. Shim JH, et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J. 2009; 28(14):2028-2041.
23. Enslen H, Brancho DM, Davis RJ. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. EMBO J. 2000;19(6):1301-1311.
24. Adams RH, et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell. 2000;6(1):109-116.
25. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell. 2000;102(2):221-231.
26. Mudgett JS, et al. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci U S A. 2000;97(19):10454- 10459.
27. Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38alpha results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med. 2000;191(5):859-870.
28. Brancho D, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003;17(16):1969-1978.
29. Turban S, et al. Insulin-stimulated glucose uptake does not require p38 mitogen-activated protein kinase in adipose tissue or skeletal muscle. Diabetes. 2005;54(11):3161-3168.
30. Beardmore VA, et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol. 2005;25(23):10454-10464.
31. Sabio G, et al. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J. 2005;24(6):1134-1145.
32. Yamaguchi K, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science. 1995;270(5244):2008-2011.
33. Shibuya H, et al. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J. 1998;17(4):1019-1028.
34. Mundlos S. Cleidocranial dysplasia: clinical and molecular genetics. J Med Genet. 1999;36(3):177-182.
35. Guy GR, et al. Sprouty: how does the branch manager work? J Cell Sci. 2003;116(Pt 15):3061-3068.
36. Warren SM, Brunet LJ, Harland RM, Economides AN, Longaker MT. The BMP antagonist noggin regulates cranial suture fusion. Nature. 2003;422(6932):625- 629.
37. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today. 2005;75(3):213-225.
38. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297-315.
39. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol. 1996;16(3):1247-1255.
40. Cuenda A, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364(2):229-233.
41. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273(3):1741-1748.
42. Bae SC, Lee YH. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene. 2006;366(1):58-66.
43. Ziros PG, et al. The bone-specific transcriptional regulator Cbfa1 is a target of mechanical signals in osteoblastic cells. J Biol Chem. 2002;277(26):23934-23941.
44. Qiao M, Shapiro P, Kumar R, Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Aktindependent signaling pathway. J Biol Chem. 2004; 279(41):42709-42718.
45. Zayzafoon M, Abdulkadir SA, McDonald JM. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem. 2004;279(5):3662-3670.
46. Abe E, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003;115(2):151-162.
47. Lee J, Mira-Arbibe L, Ulevitch RJ. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J Leukoc Biol. 2000;68(6):909-915.
48. El-Gharbawy AH, Peeden JN Jr, Lachman RS, Graham JM Jr, Moore SR, Rimoin DL. Severe cleidocranial dysplasia and hypophosphatasia in a child with microdeletion of the C-terminal region of RUNX2. Am J Med Genet A. 2010;152A(1):169-174.
49. Bergwitz C, et al. Identification of novel CBFA1/ RUNX2 mutations causing cleidocranial dysplasia. J Inherit Metab Dis. 2001;24(6):648-656.
50. Ulsamer A, et al. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem. 2008;283(7):3816-3826.
51. Acampora D, et al. Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene Dlx5. Development. 1999;126(17):3795-3809.
52. Matsumoto M, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem. 2004;279(44):45969-45979.
53. Caverzasio J, Higgins L, Ammann P. Prevention of trabecular bone loss induced by estrogen deficiency by a selective p38alpha inhibitor. J Bone Miner Res. 2008;23(9):1389-1397.
54. Mbalaviele G, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther. 2006; 317(3):1044-1053.
55. McLeod MJ. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology. 1980;22(3):299-301.
56. Jones DC, Wein MN, Glimcher LH. Schnurri-3 is an essential regulator of osteoblast function and adult bone mass. Ann Rheum Dis. 2007; 66(suppl 3):iii49-iii51.
57. Razzaque MS, Soegiarto DW, Chang D, Long F, Lanske B. Conditional deletion of Indian hedgehog from collagen type 2alpha1-expressing cells results in abnormal endochondral bone formation. J Pathol. 2005;207(4):453-461.